# COMPREHENSIVE PRECLINICAL ROADMAP
## EoE pMHC-II Nanoparticle Tolerance Therapeutics
### Ruth-Anne Pai, PhD | Built with Claude: Life Sciences Hackathon

---

## EXECUTIVE SUMMARY

This roadmap describes a 18–24 month preclinical development path to generate IND-enabling data for pMHC-II nanoparticle (NP) therapeutics targeting food-allergen-driven eosinophilic esophagitis (EoE). The design is grounded in three pillars:

1. **Disease precedent:** EoE mouse models establish murine readouts and mechanistic pathways
2. **Tolerance mechanism:** Published evidence for antigen-specific Tr1 induction via dendritic cells and multivalent antigen display
3. **Regulatory pathway:** Teplizumab and other cell-based therapies provide precedent for antigen-specific tolerance in humans

The roadmap is divided into five phases: **(1) Human functional validation**, **(2) Murine proof-of-concept**, **(3) Toxicology & biodistribution**, **(4) IND-enabling GMP manufacturing**, and **(5) Regulatory submission preparation**. Each phase includes specific decision gates and go/no-go criteria.

---

## PHASE 1: HUMAN FUNCTIONAL VALIDATION (2–4 months)

**Objective:** Confirm that wheat and soy epitopes activate food-reactive EoE T cells, and that the NP format drives IL-10 secretion (Tr1 induction) more effectively than the soluble monomer.

### 1.1 Patient Recruitment & Characterization

**Population:**
- 10–15 patients with confirmed milk-induced EoE
- Diagnostic criteria: esophageal eosinophils >15/hpf on endoscopic biopsy; clinical improvement on dairy elimination diet
- HLA-DR7 allele status: stratify by DR7+ vs. DR7− (dairy epitope is DR7-restricted)
- Baseline food-specific serum IgE (dairy, wheat, soy) to confirm sensitization

**Rationale:** EoE is food-driven but heterogeneous in antigen specificity. Patient stratification by HLA and food IgE allows matching of pMHC construct to patient genotype and sensitization profile. Milk-reactivity is the inclusion criterion; wheat/soy reactivity is measured.

**References:**
- Cianferoni et al. (2017) characterized milk-specific Th2 cells in EoE patients and provide phenotyping methodology [DOI: 10.1016/j.anai.2017.11.006]

### 1.2 Ex Vivo T Cell Assay

**Primary assay: IL-10 secretion (Tr1 induction assay)**

1. Isolate CD4+ T cells from patient PBMCs (negative selection; purity >90%)
2. Plate CD4+ cells at 2×10⁵/well in 96-well U-bottom plates
3. Stimulate with pMHC constructs:
   - **Arm A:** Soluble dairy pMHC-II monomer (positive control for Th2 vs. tolerance)
   - **Arm B:** Dairy NP-pMHC (5 copies/NP; test format)
   - **Arm C:** Wheat pMHC-II monomer and NP (test antigen)
   - **Arm D:** Soy pMHC-II monomer and NP (test antigen)
   - **Arm E:** Anti-CD3/CD28 (positive control; T cell activation)
   - **Arm F:** Unstimulated (negative control)

4. **Concentrations:** Titrate pMHC from 10 μM to 1 nM; NP-pMHC from 1 μM (on an equivalent pMHC basis) to 1 nM
5. **Culture:** 6 days at 37°C, 5% CO₂, in AIM-V or RPMI + 5% human serum
6. **Readout:** Multiplex cytokine panel on culture supernatants (IL-10, IL-5, IL-13, IFN-γ, TGF-β)
   - Assay: Luminex bead-based or ELISA

**Secondary assay: Flow cytometry (Tr1 phenotyping)**

- Day 6 post-stimulation, restimulate cells with PMA/ionomycin × 4 hours (with brefeldin A)
- Surface: CD4, CD25, CD39, CD73
- Intracellular: FoxP3, IL-10, IFN-γ, TGF-β
- Gate: CD4+ → CD25+FoxP3+ (Treg) vs. CD39+CD73+ (Tr1 candidate) → IL-10+ frequency
- Also measure: CD4+CD25+FoxP3+IL-10+ (Tr1/Treg hybrid) and CD4+CD25−IL-10+ (Tr1 proper)

**Reference:** Tolerogenic DC-mediated Tr1 induction and marker combinations [DOI: 10.3389/fimmu.2021.643240; PubMed PMID: 33679806]

### 1.3 Decision Gates (Phase 1→2)

**GO criteria (proceed to murine model):**
- Dairy pMHC-II (monomer or NP) activates CD4+ cells from ≥7/10 milk-reactive patients (IL-10+ > 100 pg/mL or >5% of CD4+ cells)
- NP format shows ≥2-fold greater IL-10 secretion than monomer in ≥5 patients
- Wheat or soy NP-pMHC activates CD4+ cells from ≥3 patients (confirming epitope capture)

**PARTIAL-GO:**
- Dairy NP-pMHC is active but wheat/soy are not → continue with dairy alone; reassess wheat/soy epitope selection

**NO-GO:**
- Dairy pMHC (monomer or NP) is inactive in >50% of patients, or NP provides no advantage over monomer → return to epitope selection and/or construct optimization

### 1.4 Timeline & Budget

- Patient recruitment: 4–8 weeks
- CD4+ isolation & culture: 1 week per batch
- Assays (Luminex/flow): 2–3 weeks
- Data analysis & decision meeting: 1 week
- **Total: 8–12 weeks; ~$15k–25k (cell processing, reagents, Luminex)**

---

## PHASE 2: MURINE PROOF-OF-CONCEPT (12–16 weeks)

**Objective:** Validate that NP-pMHC suppresses food-antigen-driven esophageal eosinophilia and expands Tr1 populations in vivo. Establish dosing, schedule, and optimal valency.

### 2.1 Mouse Strain & Sensitization Protocol

**Strain:** BALB/c mice (H-2ᵈ, Th2-biased; female, 8–10 weeks, n=8–10 per cohort)

**Rationale:** BALB/c is the standard EoE model strain; Th2-skew recapitulates human EoE immunology. Females are used to reduce cage effects and allow larger group sizes.

**Reference:** Detailed BALB/c EoE sensitization and readout protocols [DOI: 10.1002/cpz1.993; PubMed PMID: 38372429]

### 2.2 Sensitization & Dosing Schedule

**Weeks 0–2: Sensitization (oral + systemic adjuvant)**

- Oral gavage: 50 mg β-casein (or native dairy extract) + 10 μg cholera toxin (CTX) weekly × 3
- **OR** IL-33-transgenic model: use transgenic mice with inducible esophageal IL-33 (avoids adjuvant)
- **Rationale:** CTX is a Th2-polarizing adjuvant; cholera toxin is standard in food allergy models. IL-33-driven model provides Th2 without exogenous adjuvant and may better reflect human EoE.
- **Reference:** IL-33-driven EoE model without exogenous adjuvant [DOI: 10.1016/j.jaci.2024.08.026; PubMed PMID: 39265877]

**Weeks 3–6: NP-pMHC dosing (treatment)**

- IV injection (retro-orbital or tail vein) weekly × 4
- **Cohort 1:** Vehicle (PBS) — control
- **Cohort 2:** Soluble dairy pMHC-II monomer (10 μg peptide equivalent) — positive control for single-chain anergy
- **Cohort 3:** Dairy NP-pMHC (5 copies/NP; 10 μg pMHC equivalent) — test format
- **Cohort 4 (optional):** Different NP valency (3 or 8 copies/NP) to optimize
- Dose is IV (standard for NP immunotherapy); can pilot intranasal or intraperitoneal if needed

**Weeks 7–8: Observation & challenge (optional booster)**

- Optional re-challenge with oral dairy (50 mg) + CTX on week 6 to extend sensitization and test tolerance durability
- Harvest tissues at week 8

### 2.3 Primary Readout: Esophageal Histology

**Timing:** Week 8 post-sensitization

**Procedure:**
- Euthanasia; esophageal tissue harvest (full length, ~1 cm proximal to stomach)
- Fix in 10% formalin; paraffin embed; section at 5 μm
- H&E stain; count eosinophils per high-power field (hpf, 400×) in muscularis mucosae and submucosa
- Measure: Mean eosinophil density (eos/hpf) and frequency of mice with >20 eos/hpf (pathologic threshold)

**Expected outcome (based on literature):**
- Vehicle cohort: 50–150 eos/hpf (active disease)
- Soluble pMHC cohort: 30–80 eos/hpf (partial suppression via monovalent anergy)
- NP-pMHC cohort: <20 eos/hpf (strong suppression via Tr1 induction)

**Success gate:** ≥50% reduction in eosinophils (Cohort 3 vs. Cohort 1)

### 2.4 Secondary Readouts

**2.4.1 Mesenteric Lymph Node (MLN) Flow Cytometry**

- Harvest MLNs (draining node for intestinal antigen); single-cell suspension
- Surface stain: CD4, CD8, CD25, CD39, CD73, CD127 (IL-7Rα)
- Intracellular stain: FoxP3, IL-10
- Gates:
  - Treg: CD4+CD25+FoxP3+
  - Tr1-like: CD4+CD25−CD39+CD73+IL-10+
  - Effector: CD4+CD25+CD127+ IL-10−
- **Expected:** NP-pMHC cohort shows 2–5-fold expansion of Tr1/CD39+CD73+ vs. vehicle

**Rationale:** Tr1 and Treg populations in draining LN correlate with mucosal tolerance. CD39 and CD73 are ectonucleotidases that generate adenosine (immunosuppressive); their co-expression marks Tr1 cells.

**Reference:** CD39+CD73+ Tr1 identification and their role in tolerance [DOI: 10.3389/fimmu.2021.643240; PubMed PMID: 33679806]

**2.4.2 Splenocyte Proliferation Assay (Ex Vivo Restimulation)**

- Harvest spleen; isolate splenocytes
- Plate 2×10⁵ splenocytes/well; stimulate with dairy peptide (10 μM) or vehicle
- Culture 72 h; measure proliferation by CFSE dilution (flow) or [³H]-thymidine incorporation (counts)
- **Expected:** NP-pMHC cohort shows suppressed proliferation (anergy or Treg-mediated suppression) vs. vehicle

**2.4.3 Serum Antibodies**

- Harvest serum at necropsy
- Measure food-specific IgE and IgG by ELISA (using dairy, wheat, soy allergen preparations)
- **Expected:** IgE remains low (tolerance goal); IgG may rise (switched to non-inflammatory IgG4-like in mice)

**2.4.4 Esophageal Cytokine Profile (Optional)**

- Quantify IL-5, IL-13 (Th2), IL-10, TGF-β (Tr1/Treg markers) in esophageal tissue homogenates by Luminex
- **Expected:** NP-pMHC reduces IL-5/IL-13 and maintains or increases IL-10/TGF-β

### 2.5 Dosing Optimization (Cohort 4, if needed)

If Cohort 3 (5 copies/NP) shows partial but insufficient suppression, test:
- **Cohort 4a:** 3 copies/NP (lower avidity; fewer side effects if present)
- **Cohort 4b:** 8 copies/NP (higher avidity; higher risk of aggregation)

Decision: Proceed with optimal valency to Phase 3.

### 2.6 Wheat & Soy Construct Validation (Parallel or Sequential)

- If Phase 1 data support wheat/soy epitopes, run abbreviated murine studies (Cohorts 1–3, dairy only, then repeat with wheat and soy pMHC-II using same schedule)
- Timeline: parallel testing adds 12 weeks if resources allow; sequential testing extends total by 12 weeks but uses same facility/personnel

### 2.7 Decision Gates (Phase 2→3)

**GO:**
- ≥50% reduction in esophageal eosinophils (Cohort 3 vs. Cohort 1)
- ≥2-fold expansion of Tr1/CD39+CD73+ in MLN (Cohort 3 vs. Cohort 1)
- No severe adverse events (weight loss >10%, behavioral changes, mortality)

**PARTIAL-GO:**
- Eosinophil suppression is 30–50% (modest) or Tr1 expansion is <2-fold
  - → Increase NP copy number (Cohort 4b: 8 copies) or re-dose schedule
  - → Proceed to Phase 3 with modified parameters

**NO-GO:**
- <30% eosinophil suppression or evidence of unexpected toxicity
  - → Return to construct design (epitope validation, MHC binding, expression)
  - → Do NOT proceed to toxicology

### 2.8 Timeline & Budget

- Sensitization + dosing: 8 weeks
- Histology processing & flow cytometry: 3 weeks
- Data analysis & decision: 1 week
- **Total: 12 weeks per cohort; ~$40k–60k (mice, housing, histology, Luminex/flow, necropsy)**

---

## PHASE 3: TOXICOLOGY & BIODISTRIBUTION (12–16 weeks, parallel with Phase 2)

**Objective:** Generate GLP or GLP-compliant acute toxicology and biodistribution data for IND CMC section. Identify maximum tolerated dose (MTD) and organ accumulation profile.

### 3.1 Acute Systemic Toxicology (GLP-compliant)

**Study Design:**
- **Strain:** Sprague-Dawley rats (outbred; better for tox; n=6–10 per group)
- **Groups:**
  1. Vehicle (PBS)
  2. NP-pMHC: 1× anticipated clinical dose (estimated 10–100 μg pMHC/animal)
  3. NP-pMHC: 10× dose
  4. NP-pMHC: 100× dose
  - **Justification:** Dose escalation to identify NOAEL (no observed adverse effect level)
- **Route:** IV (same as clinical intent); single or repeated dosing (option: weekly × 4 to match murine schedule)
- **Observation:** Daily × 14 days; terminal necropsy at day 14

**Primary assessments:**
- **Clinical signs:** Lethargy, piloerection, diarrhea, tremor, seizure, behavioral abnormality
- **Body weight:** Daily; assess trend and stability
- **Hematology (day 7, 14):** CBC (WBC, lymphocytes, RBC, hemoglobin, platelets)
- **Clinical chemistry (day 7, 14):** BUN, creatinine, ALT, AST, ALP, albumin, glucose
- **Organ histology (day 14):** Spleen, liver, kidney, lungs, bone marrow (to assess iron oxide accumulation and inflammation)

**Decision gate:**
- **PASS:** No clinical signs of toxicity; organ weights and histology normal; hematology/chemistry within normal limits
- **CONCERN:** Mild splenomegaly (expected for iron oxide NPs; assess iron content); reversible hematology changes
- **FAIL:** Severe organ toxicity, weight loss >20%, mortality, irreversible hematology abnormalities

**Reference (regulatory precedent):** FDA guidance on nanomaterial toxicology typically requires:
- Acute tox in two species (mouse OK for one; rat required for GLP)
- Repeat-dose tox (covered by murine Phase 2)
- No standard for iron-oxide NPs; treat as medical device component

### 3.2 Biodistribution & Clearance

**Study Design:**
- **Label NP:** Radioactive label ([⁶⁴Cu] or [¹¹¹In]) or fluorescent label (AlexaFluor-647)
- **Animals:** Sprague-Dawley or BALB/c mice (n=3–4 per timepoint)
- **Dosing:** Single IV dose (10× anticipated clinical dose, or equivalent to Phase 2 murine dose)
- **Timepoints:** 4 hours, 24 hours, 7 days, 14 days, 28 days (harvest organs at each timepoint)

**Organs harvested:**
- Blood
- Spleen, liver, kidney, lungs, bone marrow, lymph nodes
- Brain, heart (controls for systemic distribution)

**Readouts:**
- Radioactivity/fluorescence per organ and per gram of tissue
- Calculate: %ID/g (percent injected dose per gram), %ID (total percent injected dose in organ)
- Kinetics: Estimate half-life (t₁/₂) and clearance pathways

**Expected outcome:**
- Spleen: highest accumulation (70–80% ID by 24 h) — consistent with reticulo-endothelial uptake
- Liver: second highest (10–20% ID)
- Kidney/blood: rapid clearance (>90% within 24 h)
- Brain: minimal (<1% ID) — good CNS safety margin
- t₁/₂ in spleen: 7–14 days (acceptable for repeat dosing every 2–4 weeks)

**Reference:** Standard for iron-oxide NPs (magnetite, maghemite) in immunotherapy; precedent from cell-labeling studies

### 3.3 Immunogenicity (Optional, but recommended)

**Study Design:**
- Repeat dosing of NP-pMHC weekly × 4 (murine Phase 2 schedule)
- Day 28 blood: quantify anti-NP IgG and anti-pMHC IgG (ELISA)
- Test for anaphylaxis during IV injection (Draize-like scoring or serum histamine)

**Expected:** Low to absent anti-NP IgG (iron oxide is minimally immunogenic); anti-pMHC antibodies are expected but should not trigger anaphylaxis

### 3.4 Timeline & Budget

- Study initiation & dosing: 2–4 weeks
- Histology/pathology review: 3–4 weeks
- Radiolabel chemistry & synthesis: 1–2 weeks (parallel)
- Biodistribution studies & analysis: 6–8 weeks
- Data compilation & report: 2 weeks
- **Total: 12–16 weeks (can be parallelized with Phase 2 murine work)**
- **Budget: $80k–150k (GLP rat study, pathology, radioactive labeling, radiochemistry)**

---

## PHASE 4: IND-ENABLING GMP MANUFACTURING (6–12 months, parallel with Phase 3)

**Objective:** Establish GMP-compliant manufacturing of NP-pMHC constructs and analytical methods for IND CMC filing. Small-scale GMP batch for Phase 1 clinical study.

### 4.1 NP Synthesis & Characterization

**NP core:** Iron oxide (Fe₃O₄ or γ-Fe₂O₃)
- **Supplier qualification:** Identify GMP-compliant iron oxide NP vendor (e.g., Nanosphere, Bangs Laboratories, custom synthesis)
- **Specs:** 20 nm ± 2 nm mean diameter; <5% polydispersity; <10 endotoxin EU/mL; sterile filterable
- **Batch testing:** TEM (size, morphology), DLS (hydrodynamic diameter), ICP-MS (iron content), endotoxin, sterility

**PEG-maleimide coating:**
- Source: PEG₂ₖ-maleimide (Supplier qualification: Sigma, Creative PEGWorks, or custom)
- Coating procedure: Standard maleimide conjugation to iron oxide surface; optimize maleimide density (target: 50–100/NP)
- Characterization: Maleimide assay (HPLC or titrimetry), particle size (DLS post-coating), zeta potential

**Storage:** Aqueous PBS, pH 7.4, 4°C, inert gas, light-protected; stability protocol per USP <1150>

### 4.2 pMHC Expression & Purification (GMP or GMP-like)

**Expression system (choose one for Phase 1):**

**Option A: E. coli (PET expression)**
- Pros: Fast, cheap, high-yield (~500 mg/L), well-established GMP precedent
- Cons: Requires refolding in vitro (glycoprotein not N-linked glycosylated); possible endotoxin concern
- Procedure:
  1. Transform BL21(DE3) with pET construct (dairy, wheat, soy variants)
  2. Culture in TB medium; induce at OD₆₀₀ ~0.6 with IPTG (0.2 mM), 20°C, 16 h
  3. Lyse in buffer; recover inclusion bodies; solubilize in guanidinium-HCl
  4. Dialyze stepwise into refolding buffer (pH 8.5, reduced/oxidized L-cysteine to aid disulfide formation)
  5. Purify by Ni-NTA (His6 tag), then SEC (desalt, buffer exchange)
  6. Endotoxin removal: Polymyxin B column or ion-exchange
- Expected yield: 300–500 mg pMHC per liter culture
- Cost: ~$2–3k per batch

**Option B: Insect cells (baculovirus; Sf9)**
- Pros: Proper disulfide formation, reduced endotoxin, glycosylation if needed
- Cons: Slower, lower yield (~50 mg/L), more expensive (~$10k+)
- Use if E. coli refolding is unsuccessful

**Option C: Mammalian (CHO or HEK293)**
- Pros: Native folding, best efficacy but slower and expensive
- Cons: Least suitable for GMP small-scale; use only if E. coli fails

**Recommendation:** Start with E. coli for Phase 1; switch to mammalian if efficacy issues arise.

**Purification & QC:**
1. Ni-NTA column (His6 tag capture)
2. SEC (Sepharose 6B or similar) for buffer exchange and aggregation removal
3. Ion-exchange (optional; further endotoxin removal)
4. Sterile 0.22 μm filtration

**QC Specifications:**
- **Identity:** SDS-PAGE (reducing & non-reducing) — expected MW 454 aa × 110 Da/aa ≈ 50 kDa ± 2 kDa
- **Purity:** ≥95% by SEC and SDS-PAGE (silver stain)
- **Endotoxin:** <10 EU/μg (LAL, Limulus Amebocyte Lysate)
- **Sterility:** Membrane filtration (0.22 μm) + 14-day fluid thioglycollate medium
- **Potency:** CD4+ T cell activation assay with food-reactive patient cells (IL-10 secretion or proliferation)
- **Protein concentration:** BCA or Bradford assay

### 4.3 NP–pMHC Conjugation & Characterization

**Conjugation procedure (GMP-style):**
1. Mix maleimide-coated NP (stock) with pMHC construct at molar ratio (10:1 to 50:1 pMHC:NP)
2. Incubate in PBS, pH 7.0–7.5, RT, 4 hours (under mild stirring or vortex, inert gas atmosphere)
3. Quench with DTT (excess to block unreacted maleimides)
4. Purify by SEC (Sepharose 6B, 10 mL column) — NP-pMHC elutes in void volume; unreacted pMHC in included volume
5. Collect void-volume fractions; pool and concentrate if needed

**QC Specifications:**
- **Copy number:** Amino-acid analysis (post hydrolysis) to quantify pMHC per NP; target 5 ± 1 copies/NP
- **Aggregation:** DLS, TEM (check for aggregates)
- **Endotoxin:** <10 EU/μg (total, NP + pMHC)
- **Sterility:** 0.22 μm filter + 14-day fluid thioglycollate
- **Potency:** CD4+ T cell IL-10 assay (must be ≥2-fold vs. monomeric control)
- **Stability:** Stored in PBS + 0.1% BSA + 0.05% Tween-80, 4°C; test for >90% potency at 6 months

### 4.4 GMP Batch (IND Phase 1)

**Scale-up:** 1 gram pMHC-equivalent starting material
- E. coli production: ~2 liters culture
- Conjugation yield: ~80% (assuming losses in purification)
- Final NP-pMHC yield: ~0.8 grams

**Filling:**
- Aliquot 100 μL per vial (100 μg pMHC-NP equivalent per dose)
- Freeze-drying protocol (optional; aqueous formulation may be acceptable if pH 7.4 + cryoprotectant works)
- Label, stability testing

**Documentation (for IND CMC):**
1. NP synthesis: SOPs, raw material suppliers (COA), in-process controls
2. pMHC expression: Construct design, expression host characterization, purification SOPs, equipment validation
3. Conjugation: Chemistry rationale, stoichiometry control, purification methods
4. Finished product: Specifications (identity, purity, potency, endotoxin, sterility)
5. Stability data: Real-time stability at 4°C (target: 6-month shelf life minimum)

### 4.5 Timeline & Budget

- NP sourcing & qualification: 2–4 weeks
- pMHC expression & scale-up: 6–8 weeks
- Conjugation optimization: 2–4 weeks
- GMP batch production: 4–6 weeks
- QC & stability protocol initiation: 2–4 weeks
- **Total: 16–26 weeks (4–6 months)**
- **Budget: $50k–100k (NP purchase, expression, purification, QC testing, GMP facilities)**

---

## PHASE 5: REGULATORY SUBMISSION PREPARATION (2–4 months, parallel with Phase 4)

**Objective:** Compile all preclinical & manufacturing data into an IND-enabling dossier. Identify CMC and safety gaps. Engage FDA if needed (pre-IND meeting optional).

### 5.1 IND Package Contents (FDA Guidance)

**CMC Section:**
- Chemistry: NP core synthesis, PEG coating, pMHC expression, conjugation chemistry
- Manufacturing: Process validation, equipment specs, in-process controls, final product specs
- Controls: Analytical methods (HPLC, SDS-PAGE, potency assay, endotoxin), acceptance criteria
- Stability: Real-time and accelerated stability data (6 months minimum)

**Pharmacology/Toxicology:**
- Nonclinical pharmacology: Mechanism of action (Tr1 induction, in vitro data from Phase 1 human assay)
- In vivo pharmacology: Murine efficacy (Phase 2) — dose-response, mechanism
- Toxicology: Acute GLP toxicology (Phase 3), repeat-dose from murine (Phase 2), special toxicology (reproductive, genotoxicity — not required for antigen-specific tolerance)
- Biodistribution: Phase 3 clearance kinetics

**Clinical Section:**
- Protocol: Phase 1 safety/tolerability in EoE patients
- Pharmacology/toxicology summary: Risk mitigation (iron-oxide accumulation, immunogenicity)
- Literature review: Precedent for antigen-specific tolerance (teplizumab, abatacept, VIA) and food-allergen pMHC therapeutics

### 5.2 Pre-IND Meeting (Optional)

**Timing:** 30 days after filing Pre-IND request with FDA

**Topics to discuss:**
1. Acceptability of nonclinical data package (especially whether additional tox studies are needed)
2. Clinical trial design (safety endpoints, dose escalation strategy, patient population)
3. CMC manufacturing approach (is small-scale GMP sufficient, or full GMP required?)
4. Precedent for food-allergen-specific tolerance (EoE is not commonly addressed; FDA may request additional patient characterization or biomarkers)

**Expected outcome:** Clear path to IND; possible requests for additional nonclinical data (e.g., repeat-dose tox in rodents, specific allergen-challenge testing)

### 5.3 Clinical Trial Design (Draft for IND)

**Phase 1 Study Outline:**

**Title:** A Phase 1, Open-Label, Dose-Escalation Study of [pMHC-NP-001] (Dairy-Allergen-pMHC-II Nanoparticle) in Subjects with Milk-Induced Eosinophilic Esophagitis

**Objectives:**
- Primary: Safety and tolerability (adverse events, laboratory abnormalities, antidrug antibodies)
- Secondary: Biomarker response (esophageal eosinophil count, food-specific T cell IL-10, serum IgE/IgG)
- Exploratory: Clinical efficacy (symptom improvement, food reintroduction tolerance)

**Design:**
- 3 dose cohorts (3+3 design: 3 patients per cohort; if ≥2 DLTs, expand to 6)
  - Cohort 1: 10 μg pMHC-NP IV, weekly × 4
  - Cohort 2: 30 μg pMHC-NP IV, weekly × 4
  - Cohort 3: 100 μg pMHC-NP IV, weekly × 4
- Observation: 12 weeks post-last dose
- N = 9–18 subjects (depending on DLT)

**Population:**
- Milk-induced EoE (esophageal eosinophils >15/hpf); HLA-DR7+ (enrichment strategy)
- Age 18–65
- Baseline esophageal biopsy; repeat at week 12
- Diary: food intake, symptom score (dysphagia, chest pain, regurgitation)

**Safety monitoring:**
- Weekly labs during dosing (CBC, CMP, LFTs)
- Monthly monitoring during observation phase
- Antidrug antibodies (anti-NP, anti-pMHC) at baseline, week 4, week 12, week 24
- Adverse event assessment per CTCAE v5.0

**Stopping rules:**
- Grade 3+ non-hematologic toxicity (any)
- Grade 4 hematologic toxicity
- Anaphylaxis
- >1 DLT in first 3 subjects of a cohort → declare cohort unacceptable

**Biomarkers (secondary/exploratory):**
- Esophageal eosinophil count (central reading of biopsy)
- Food-specific T cell IL-10 (ex vivo CD4+ assay with dairy pMHC)
- Serum food-specific IgE/IgG
- Circulating Tr1 markers (CD39+CD73+, IL-10 intracellular stain) — optional

---

## SUMMARY TABLE: PHASES & DECISION GATES

| Phase | Timeframe | Cost | Primary Gate | GO Criteria | PARTIAL-GO | NO-GO |
|---|---|---|---|---|---|---|
| **1. Human validation** | 8–12 weeks | $15–25k | CD4+ IL-10 response | Dairy IL-10+ in ≥7/10; NP ≥2× monomer | Dairy works; wheat/soy inactive | <30% response |
| **2. Murine POC** | 12 weeks | $40–60k | Eosinophil suppression | ≥50% reduction; Tr1 ≥2× | 30–50% reduction | <30% reduction |
| **3. Tox/biodist** | 12–16 weeks | $80–150k | NOAEL; clearance kinetics | No MTD hit; t₁/₂ 7–14d spleen | Mild splenomegaly | Organ toxicity |
| **4. GMP manufacturing** | 16–26 weeks | $50–100k | Batch release QC | ≥95% purity; 5±1 copies/NP; potency | Suboptimal copies | Failed assays |
| **5. Reg. submission** | 8–12 weeks | $10–20k | IND acceptance | FDA acknowledges; no major holds | Requests additional data | Deficient IND |

---

## RISK MITIGATION & CONTINGENCIES

### Risk 1: Wheat/Soy epitopes don't activate patient T cells (Phase 1 NO-GO on those antigens)
- **Mitigation:** Proceed with dairy alone; reassess wheat/soy epitope selection using IEDB + experimental HLA-peptide binding assays
- **Contingency:** Focus Phase 1 clinical trial on milk-reactive EoE (still represents ~50% of food-triggered cases)

### Risk 2: NP format provides no advantage over soluble monomer (Phase 1 PARTIAL-GO)
- **Mitigation:** Test higher NP valencies (8 copies/NP) or alternative linker chemistries to increase avidity
- **Contingency:** Proceed with soluble monomer format if NP optimization is unsuccessful; simpler manufacturing & regulatory path

### Risk 3: Murine eosinophil suppression is modest (Phase 2 PARTIAL-GO)
- **Mitigation:** Increase dosing frequency (twice-weekly instead of once-weekly) or NP copy number
- **Contingency:** If still <30% suppression, revisit murine model choice (consider IL-33 transgenic or OVA-sensitized SCID mice with human T cell engraftment for more physiologic response)

### Risk 4: NP accumulates excessively in spleen, not clearing within 28 days (Phase 3 blocker)
- **Mitigation:** Reduce NP size (10 nm instead of 20 nm) or incorporate PEG brush with longer chains (PEG₅ₖ) for slower uptake
- **Contingency:** Proceed to Phase 1 with informed risk discussion (spleen iron accumulation is manageable in short-term trial; long-term repeat dosing may require iron-chelation therapy or modified dosing schedule)

### Risk 5: Phase 1 anaphylaxis or other severe immune event
- **Mitigation:** Slow dose escalation (3+3 design); prescreen for anti-pMHC IgE; consider steroid/antihistamine prophylaxis
- **Contingency:** Halt trial; investigate epitope cross-reactivity to other food antigens; consider alternative epitope or format

---

## EXPECTED MILESTONES & DECISION POINTS

**Month 0–3:** Phase 1 human validation completed; GO/NO-GO for wheat/soy epitopes
**Month 4–7:** Phase 2 murine POC completed; go/no-go for NP format vs. monomer
**Month 4–8:** Phase 3 tox & biodistribution in parallel; NOAEL & clearance kinetics established
**Month 8–14:** GMP manufacturing batch in production; analytical methods validated
**Month 10–14:** IND dossier compiled; Pre-IND meeting (if requested)
**Month 14–18:** IND accepted by FDA (assuming no major holds); Phase 1 clinical trial initiation
**Month 18–24:** Phase 1 completion; data analysis & regulatory decision on Phase 2 expansion

---

## COSTS & FUNDING REQUIREMENTS

| Phase | Estimated Cost |
|---|---|
| Phase 1 (human) | $15–25k |
| Phase 2 (murine) | $40–60k |
| Phase 3 (tox/biodist) | $80–150k |
| Phase 4 (GMP manufacturing) | $50–100k |
| Phase 5 (regulatory prep) | $10–20k |
| **TOTAL preclinical + manufacturing** | **$195–355k** |

**Funding strategy:**
- NIH SBIR/STTR (if forming biotech entity; typically $150–225k for Phase 1)
- Foundation grants (Digestive Disease/Allergy foundations; ~$50–100k)
- Angel/seed funding for biotech startup
- Cost-share with academic collaborators

---

## CONCLUSION

This 18–24 month roadmap provides a clear path from in silico design to IND-enabling data. The design is grounded in published precedent for EoE murine models, antigen-specific tolerance via Tr1 induction, and multivalent NP immunotherapy. Key decision gates allow for rapid iteration (e.g., epitope selection, NP valency optimization) if individual phases underperform.

**The critical path is:**
1. **Phase 1 (human functional validation):** Confirms epitope specificity and NP advantage
2. **Phase 2 (murine POC):** Validates mechanism and dosing
3. **Phase 3 (tox/biodist):** Demonstrates safety
4. **Phase 4 (GMP manufacturing):** Enables clinical manufacturing
5. **Phase 5 (regulatory):** Prepares IND package

**Expected outcome:** IND acceptance within 18–24 months, enabling Phase 1 clinical trial in milk-reactive EoE patients by mid-2027.